

AMENDMENTS TO CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application.

1. (Cancelled)
2. (New) An antibody or a fragment thereof, wherein the antibody or the fragment thereof recognizes a mammalian GBS toxin receptor or a fragment thereof.
3. (New) The antibody or the fragment thereof of Claim 2, wherein the antibody or the fragment thereof recognizes a fragment of SEQ ID NO:4 or SEQ ID NO:8.
4. (New) The antibody or the fragment thereof of Claim 2, wherein the antibody or the fragment thereof recognizes a fragment of SEQ ID NO:4 comprising amino acid residues 71 to 84 or amino acid residues 7 to 22.
5. (New) The antibody or the fragment thereof of Claim 2, wherein the mammalian GBS toxin receptor is expressed on a surface of a cell.
6. (New) The antibody or the fragment thereof of Claim 2, wherein the antibody is a monoclonal antibody or a polyclonal antibody.
7. (New) The antibody or the fragment thereof of Claim 2, wherein the antibody or the fragment thereof is generated by a method comprising immunizing an animal with the mammalian GBS toxin receptor or the fragment thereof.
8. (New) The antibody or the fragment thereof of Claim 2, wherein the antibody is a rabbit antibody or a mouse antibody.

9. (New) The antibody or the fragment thereof of Claim 2, wherein the antibody recognizes an extracellular domain of the GBS toxin receptor or the fragment thereof.
10. (New) An inhibitor of binding of a GBS toxin to a mammalian GBS toxin receptor.
11. (New) The inhibitor of Claim 10, wherein the inhibitor is an antibody or a fragment thereof.
12. (New) The inhibitor of Claim 11, wherein the antibody or the fragment thereof recognizes a fragment of SEQ ID NO:4 or SEQ ID NO:8.
13. (New) A pharmaceutical composition for inhibition of a GBS toxin receptor, comprising an inhibitor of the GBS toxin receptor, in an amount effective to inhibit the GBS toxin receptor, and a pharmaceutically acceptable carrier.
14. (New) The composition of Claim 13, wherein the inhibitor is an antibody or a fragment thereof that recognizes the mammalian GBS toxin receptor or a fragment thereof.
15. (New) The composition of Claim 14, wherein the antibody or the fragment thereof recognizes a fragment of SEQ ID NO:4 or SEQ ID NO:8.
16. (New) The composition of Claim 15, wherein the antibody or the fragment thereof recognizes a fragment of SEQ ID NO:4 comprising amino acid residues 71 to 84 or 7 to 22 .
17. (New) A composition for detection of a GBS toxin receptor or a fragment thereof, comprising a reagent for detection of the GBS toxin receptor or the fragment thereof.

Second Preliminary Amendment

Serial No. 10/823,506

Page 4

18. (New) The composition of Claim 18, wherein the reagent for detection of the GBS toxin receptor or the fragment thereof is an antibody or a fragment thereof.
19. (New) The composition of Claim 18, wherein the antibody or the fragment thereof recognizes a mammalian GBS toxin receptor or a fragment thereof.
20. (New) The composition of Claim 19, wherein the antibody or the fragment thereof recognizes a fragment of SEQ ID NO:4 or SEQ ID NO:8.
21. (New) The composition of Claim 20, wherein the antibody or the fragment thereof recognizes a fragment of SEQ ID NO:4 comprising amino acid residues 71 to 84 or 7 to 22.
22. (New) The composition of Claim 18, wherein the GBS toxin receptor or the fragment thereof is detected in a cell or a tissue of an animal or a human.